PTC Therapeutics (PTCT) Reports Q1 Loss Per Share of $1.15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Roth Capital Downgrades PTC Therapeutics (PTCT) to Neutral
May 5, 2015 7:05 AM EDTRoth Capital downgraded PTC Therapeutics (NASDAQ: PTCT) from Buy to Neutral with a price target of $63.00 (from $75.00).
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $60.84 yesterday.
... More